Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21569633 | 0.95 | CYP2C19 (0.56) | CYP2C19MAPTTSHRHPGDGAA | |
| SCHEMBL13746185 | 0.86 | CYP2C19 (0.62) | CYP2C19MAPTTSHRHPGDGAA | |
| SCHEMBL13006880 | 0.84 | NPSR1 (0.67) | MAPTTSHRHPGDALDH1A1 | |
| SCHEMBL28499155 | 0.84 | MTNR1A (0.61) | CYP2C19MAPTTSHRHPGDGAA | |
| SCHEMBL18342995 | 0.81 | EPHX1 (0.63) | CYP2C19TSHRHPGDALDH1A1L3MBTL1 | |
| SCHEMBL20160095 | 0.81 | CYP2C19 (0.59) | CYP2C19MAPTTSHRHPGDGAA | |
| SCHEMBL13006889 | 0.81 | ALDH1A1 (0.55) | CYP2C19MAPTTSHRHPGDGAA | |
| SCHEMBL18825962 | 0.80 | CHRM4 (0.74) | — | |
| SCHEMBL13006888 | 0.80 | KDM4E (0.54) | CYP2C19TSHRHPGDGAAALDH1A1 | |
| SCHEMBL5815460 | 0.80 | EPHX1 (0.66) | CYP2C19HPGDALDH1A1FKBP1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2022-06-28 | — | — | US | disclosed |
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | TLR7, TLR9, TLR1 | CYP2C19 3685/4885MAPT 4108/4885TSHR 788/4885 |
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | TLR7, TLR9, TLR1 | CYP2C19 3685/4885MAPT 4108/4885TSHR 788/4885 |
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | TLR9, TLR7, TLR8 | CYP2C19 3590/4885MAPT 4005/4885TSHR 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.